{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.01","upperLimit":"0.52","value":"0.17"},{"groupId":"OG001","lowerLimit":"0.07","upperLimit":"0.58","value":"0.3"},{"groupId":"OG002","lowerLimit":"0.05","upperLimit":"0.75","value":"0.4"},{"groupId":"OG003","lowerLimit":"0.2","upperLimit":"0.97","value":"0.8"},{"groupId":"OG004","lowerLimit":"0.01","upperLimit":"0.58","value":"0.2"},{"groupId":"OG005","lowerLimit":"0.17","upperLimit":"0.71","value":"0.45"},{"groupId":"OG006","lowerLimit":"0.47","upperLimit":"0.99","value":"0.9"},{"groupId":"OG007","lowerLimit":"0.2","upperLimit":"0.97","value":"0.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"5"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20%increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.\n\nAge group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG000","title":"Adipocytic Tumors Group"},{"description":"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.\n\nAge group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG001","title":"Vascular Tumors Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG002","title":"Undifferentiated Pleomorphic Sarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG003","title":"Synovial Sarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG004","title":"Osteosarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG005","title":"Other Sarcomas Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG006","title":"Alveolar Soft-part Sarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"OG007","title":"Chordomas Group"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"proportion of participants"}